<?xml version='1.0' encoding='utf-8'?>
<document id="8846620"><sentence text="Fluvoxamine. A review of global drug-drug interaction data."><entity charOffset="0-11" id="DDI-PubMed.8846620.s1.e0" text="Fluvoxamine" /></sentence><sentence text="The overall reporting rate of drug-drug interactions with fluvoxamine is very low: only 73 cases have been identified from an estimated exposure of over 8 million patients worldwide"><entity charOffset="58-69" id="DDI-PubMed.8846620.s2.e0" text="fluvoxamine" /></sentence><sentence text=" The reporting rate is similar in men and women, and most events relate to the use of fluvoxamine in conjunction with psychotropic compounds and anticoagulants"><entity charOffset="86-97" id="DDI-PubMed.8846620.s3.e0" text="fluvoxamine" /></sentence><sentence text=" Two deaths have been documented" /><sentence text=" One involved a female patient who was given concomitant tryptophan and reportedly developed neuroleptic malignant syndrome"><entity charOffset="57-67" id="DDI-PubMed.8846620.s5.e0" text="tryptophan" /></sentence><sentence text=" The causative role of fluvoxamine/tryptophan interaction in this case is unknown"><entity charOffset="23-34" id="DDI-PubMed.8846620.s6.e0" text="fluvoxamine" /><entity charOffset="35-45" id="DDI-PubMed.8846620.s6.e1" text="tryptophan" /><pair ddi="false" e1="DDI-PubMed.8846620.s6.e0" e2="DDI-PubMed.8846620.s6.e0" /><pair ddi="false" e1="DDI-PubMed.8846620.s6.e0" e2="DDI-PubMed.8846620.s6.e1" /></sentence><sentence text=" The other reported death was considered to be unrelated to fluvoxamine"><entity charOffset="60-71" id="DDI-PubMed.8846620.s7.e0" text="fluvoxamine" /></sentence><sentence text=" Fluvoxamine interactions with anti-epileptic or antidepressant drugs resulted in elevated plasma concentrations of the target drug and/or clinical symptoms, while interactions with neuroleptic or anticoagulant agents mostly resulted in clinical symptoms"><entity charOffset="1-12" id="DDI-PubMed.8846620.s8.e0" text="Fluvoxamine" /></sentence><sentence text=" Fluvoxamine increased plasma concentrations of tricyclic antidepressants by varying extents, particularly those of clomipramine (maximum reported increase 8-fold)"><entity charOffset="1-12" id="DDI-PubMed.8846620.s9.e0" text="Fluvoxamine" /><entity charOffset="116-128" id="DDI-PubMed.8846620.s9.e1" text="clomipramine" /><entity charOffset="156-162" id="DDI-PubMed.8846620.s9.e2" text="8-fold" /><pair ddi="false" e1="DDI-PubMed.8846620.s9.e0" e2="DDI-PubMed.8846620.s9.e0" /><pair ddi="false" e1="DDI-PubMed.8846620.s9.e0" e2="DDI-PubMed.8846620.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8846620.s9.e0" e2="DDI-PubMed.8846620.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8846620.s9.e1" e2="DDI-PubMed.8846620.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8846620.s9.e1" e2="DDI-PubMed.8846620.s9.e2" /></sentence><sentence text=" Generally, clinical symptoms were infrequent and varied widely; no symptom clusters were identified" /><sentence text=" Those agents metabolised by cytochrome P450 1A2 isoenzyme appear most likely to be involved in drug-drug interactions with fluvoxamine"><entity charOffset="124-135" id="DDI-PubMed.8846620.s11.e0" text="fluvoxamine" /></sentence><sentence text="" /></document>